Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.

US President Donald Trump announced plans to impose tariffs on imported computer chips pharmaceuticals and steel aiming to ...

The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few ...

Marks a significant advancement in offering new treatment options for patients with rare diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and ...

Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...

SEOUL, Feb. 6 (Yonhap) -- South Korean stocks traded higher late Thursday morning led by solid gains of major tech shares.

Samsung Bioepis announced on the 12th that it has signed a commercialization partnership agreement with Teva Pharmaceutical Industries to enter the U.S. market with the rare disease treatment ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

Pharmacies have been given instructions by the General Pharmaceutical Council on new steps they must follow before ...

Samsung Biologics has become the first among domestic pharmaceutical corporations to join the annual revenue "4 trillion club." Samsung Biologics noted that its revenue for 2024 recorded 4.5473 ...